Use of polylactic acid and copolymer thereof in preparation of drugs for promoting tendon / ligament growth

MYPI2026000133A0Undetermined Publication Date: 2025-01-10CHANGCHUN SINOBIOMATERIALS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026000133
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-10
Filing Date
2024-07-04
Publication Date
2025-01-10

AI Technical Summary

Technical Problem

The prior art In the treatment of tendon/ligament injury, secondary injury caused by autologous tendon transplantation, immune rejection and infection risk of allogeneic tendons, inflammation caused by degradation products of artificial ligament, and difficulty in tissue regeneration, lack of effective promotion of tendons /Ligament growth method.

Method used

Polylactic acid and its copolymers, especially poly-L-lactic acid and its microsphere preparations, are used to promote the growth of tendons/ligaments by injecting into the lesion site, and their excellent biocompatibility and biodegradability. The preparation includes microspheres, micelles, gels, etc., with a particle size of 17μm to 60μm and a degradation time of 1 to 2 years. It contains auxiliary materials such as surfactants, stabilizers and antiswelling ingredients, and is used for mass production of the company. and clinical applications.

Benefits of technology

Significantly promote tendon/ligament cell proliferation and tissue regeneration, reduce the risk of refraction, and provide a new effective way to treat tendon/ligament injury, avoid vascular risk caused by too small microsphere particle size, and improve biological integration .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2026000133_DRAWING_001
    Figure PI2026000133_DRAWING_001
  • Figure PI2026000133_DRAWING_002
    Figure PI2026000133_DRAWING_002
Patent Text Reader

Abstract

Provided is a use of polylactic acid and a copolymer thereof in preparation of drugs for promoting tendon / ligament growth. The molecular weight of the polylactic acid is 400-300000 Da, and preferably 5000-20000 Da. The polylactic acid copolymer comprises one or more of a poly(lactic acid-glycolic acid) copolymer, a poly(lactic acid-ethylene glycol) copolymer, a poly(ethylene glycol-lactic acid-glycolic acid) copolymer, a polylactic acid-chitosan copolymer, and a lactide-caprolactone copolymer, preferably a poly(lactic acid-glycolic acid) copolymer. It is found for the first time that the polylactic acid and the copolymer thereof have the effect of promoting ligament / tendon growth, and a new approach is provided for treatment of ligament / tendon injury. Fig.3
Need to check novelty before this filing date? Find Prior Art

Description

Application of polylactic acid and its copolymers in the preparation of drugs promoting tendon / ligament growth

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. 202310840075.X filed on July 10, 2023, entitled “Application of polylactic acid and its copolymers in the preparation of drugs promoting tendon / ligament growth”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present invention relates to the technical field of polymer drugs, in particular to the application of polylactic acid and its copolymers in the preparation of drugs for promoting tendon / ligament growth. Background Art

[0004] Joint and ligament injuries are common sports injuries, with a significant number of new cases reported annually worldwide, making them a global health concern. Tendons and ligaments are fibrous connective tissues that connect muscle to bone, or bone to bone, providing traction and stability. Injury can significantly reduce a patient's quality of life and, in severe cases, lead to functional disability.

[0005] In order to restore the function of the knee joint after joint ligament injury, ACL reconstruction surgery is often required. The current clinical reconstruction grafts include autologous tendons, allogeneic tendons and artificial ligaments. Among them, autologous tendons are taken from the patient's own hamstrings, gracilis muscles, etc. Autologous tendon transplantation will cause secondary damage to the patient, which is not conducive to later recovery. At the same time, the length and diameter of the autologous tendon are limited by the sampling site, making it difficult to meet the usage standards; allogeneic tendons have the risk of immune rejection and infection in clinical use, and the donor source is limited; artificial ligaments are usually high-molecular organic materials, and their degradation products will change the local microenvironment of the joint and easily cause aseptic inflammation. In addition, tendons, cartilage and other tissues lack blood supply, so tissue regeneration is difficult, and grafts are mainly functional replacements and have no ability to promote tissue regeneration. Therefore, the biological integration of tissues and grafts is difficult, and long-term implantation still has the risk of re-rupture.

[0006] Polylactic acid (PLA), with the molecular formula (C3H4O2)n, is primarily prepared by the polymerization of lactic acid or the ring-opening polymerization of lactide. PLA and its copolymers not only possess excellent mechanical strength and chemical stability, but also possess good biocompatibility and biodegradability. In recent years, extensive research has been conducted both domestically and internationally on their biomedical applications. They have found widespread application in surgical sutures, bone repair materials, controlled drug release systems, and functional tissue scaffolds (such as artificial bone and skin).

[0007] Biodegradable and biocompatible poly(L-lactic acid) microparticles (trade name Sculptra™) were approved by the US FDA in 2004 for filling sagging skin caused by facial fat atrophy in AIDS patients. Clinicians also use them for aging-related fat atrophy and localized fat atrophy in healthy individuals. In 2009, the US FDA officially approved poly(L-lactic acid) fillers for improving nasolabial folds. However, there are no reports in the prior art regarding the effects of poly(lactic acid) and its copolymers on ligament or tendon repair.

[0008] Summary of the Invention

[0009] In view of the shortcomings of the prior art, the present invention provides the use of polylactic acid and its copolymers in the preparation of drugs for promoting tendon / ligament growth, which provides a new approach for promoting tendon / ligament growth.

[0010] The purpose of the present invention is to provide the use of polylactic acid and its copolymers in the preparation of tendon / ligament growth promoting drugs, wherein the molecular weight of the polylactic acid is 400-300000Da, preferably, the molecular weight is 5000-20000Da.

[0011] Furthermore, the polylactic acid is poly-L-lactic acid.

[0012] Furthermore, the polylactic acid copolymer includes one or more of polylactic acid glycolic acid copolymer, polylactic acid polyethylene glycol copolymer, polyethylene glycol polylactic acid glycolic acid copolymer, polylactic acid-chitosan copolymer, and lactide-caprolactone copolymer.

[0013] Preferably, the polylactic acid copolymer is a polylactic acid-glycolic acid copolymer.

[0014] Furthermore, the polylactic acid and its copolymers are in the form of preparations.

[0015] Furthermore, the preparation includes microspheres, micelles, and gels, with microspheres being preferred. The preparation process of microspheres is simple and can be mass-produced; and microspheres are easy to store and are not easily deteriorated.

[0016] Furthermore, the particle size range of the microspheres is 17μm to 60μm, preferably the particle size range of the L-polylactic acid microspheres is 24μm to 55μm, and preferably the particle size range of the polylactic acid glycolic acid microspheres is 17μm to 56μm. Microspheres in this particle size range can be injected with a needle of 26G or above, without causing invasive damage to the treatment site, and avoiding microspheres with too small a particle size. The degradation time of microspheres in this particle size range is within 1 to 2 years, which can better meet clinical needs. It also reduces the risk of entering blood vessels due to microspheres with too small a particle size.

[0017] The formulation further includes excipients, which include at least one of a stabilizer, a filler, a binder, a surfactant, and a lubricant.

[0018] Furthermore, the surfactant includes one or more of polyethylene glycol, sodium lauryl sulfate, Tween, and Span; the stabilizer includes one or two of carboxymethyl cellulose and mannitol; the filler includes one or more of lactose, mannitol, cyclodextrin, and sorbitol; the binder includes one or more of hydroxypropyl cellulose, methyl cellulose, and polyvinyl pyrrolidone; and the lubricant includes one or more of magnesium stearate, calcium stearate, and stearic acid.

[0019] Furthermore, the preparation further comprises a first active ingredient, and the first active ingredient has the effect of reducing swelling and relieving pain.

[0020] Furthermore, the first active ingredient includes celecoxib, loxoprofen sodium, phenylbutazone, ibuprofen, and etoricoxib.

[0021] Furthermore, the dosage of L-lactic acid in the poly-L-lactic acid and its copolymers during at least one administration of the preparation is 8 to 3000 mmol / L, preferably 250 to 750 mmol / L.

[0022] In a specific embodiment of the present invention, the preparation is injected into the diseased tendon, and the dosage of the preparation is calculated according to the mass of the tendon at the diseased site.

[0023] In some embodiments, the above-mentioned preparation is an injectable preparation, and the dosage of poly-L-lactic acid or its copolymer in the injectable preparation is 8 to 3000 mmol / L, preferably 250 to 750 mmol / L or 50 to 100 mmol / L, and more preferably 50 to 90 mmol / L, 50 to 80 mmol / L, or 50 to 70 mmol / L, based on the dosage of L-lactic acid. The above-mentioned injectable preparations include, but are not limited to, liquid injections and powder injections. In the case of powder injections, the above dosage represents the dosage after reconstitution of the dry powder.

[0024] Compared with the prior art, the present invention has the following beneficial effects: the present invention is the first to discover that polylactic acid and its copolymers have the effect of promoting tendon / ligament growth, providing a new approach for the treatment of tendon / ligament injuries. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] FIG1 is a SEM image of PLLA microspheres in Example 1 of the present invention.

[0026] FIG2 is a SEM image of PLGA microspheres in Example 2 of the present invention.

[0027] FIG3 is a graph showing the proliferation results of tenocytes under the action of PLLA microspheres at different concentrations in Example 3 of the present invention.

[0028] FIG4 is a staining image of tendons on the experimental side (0.5 mg PLLA microspheres) and the control side (normal saline) in Example 4 of the present invention; red represents collagen fibers.

[0029] FIG5 is a staining image of tendons on the experimental side (0.5 mg PLGA microspheres) and the control side (normal saline) in Example 4 of the present invention; red represents collagen fibers. DETAILED DESCRIPTION

[0030] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.

[0031] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0032] Example 1 Preparation of L-polylactic acid microspheres

[0033] 10 g of L-polylactic acid (PLLA) (molecular weight 20,000 Da) was dissolved in 150 mL of dichloromethane, and then the above polymer solution was added to 2000 mL of a 1.0% polyvinyl alcohol aqueous solution. After emulsification at 5000 rpm / min for 5 minutes, the mixture was stirred at 1000 rpm for 6 hours to remove the dichloromethane, and finally L-polylactic acid microspheres were obtained.

[0034] The prepared L-polylactic acid microspheres were observed by scanning electron microscopy and the particle size was calculated. The photo of the microspheres is shown in Figure 1. As shown in Figure 1, the particle size range of the microspheres is 24.31-54.29 μm.

[0035] Example 2 Preparation of polylactic acid glycolic acid microspheres

[0036] 10 g of poly(lactic-co-glycolic acid) (PLGA) (molecular weight 20,000 Da) was dissolved in 150 mL of dichloromethane. The polymer solution was then added to 2000 mL of a 0.5% aqueous solution of polyvinyl alcohol. The mixture was emulsified at 5000 rpm / min for 5 minutes and then stirred at 1000 rpm for 6 hours to remove the dichloromethane. PLGA microspheres were obtained, in which the molar content of L-lactic acid was 0.0104 mol / g.

[0037] The prepared polylactic acid microspheres were observed by scanning electron microscopy and the particle size was calculated. The photo of the PLGA microspheres is shown in Figure 2. As shown in Figure 2, the particle size of the microspheres ranged from 17.89 to 55.87 μm.

[0038] Example 3 Cell experiment to promote tendon growth

[0039] The subscapularis tendon of a 2-week-old rabbit was taken and tenocytes were extracted. The CCK-8 method was used to test the proliferation of rabbit tendon cells on PLLA microspheres. First, 5 mg, 10 mg and 20 mg of the polymer microspheres prepared in Example 1 were added to the bottom of a 96-well plate, and 5 parallel wells were set for each sample. Then 200 μL of cell suspension with a concentration of 4×104 / mL was added to each sample well and placed in a cell culture incubator. After incubation in the dark for 1, 3 and 5 days, the cell culture medium in the 96-well plate was taken out and placed in an empty 96-well plate. 20 μL of CCK-8 solution was added to each well. After incubation in the dark for 4 hours, the absorbance at 450 nm was tested by an enzyme reader, and the proliferation results of rabbit tendon cells on PLLA microsphere samples with different concentrations were finally calculated. The results are shown in Figure 3.

[0040] As shown in Figure 3, as the concentration of PLLA microspheres increases, the number of tenocytes also gradually increases. Therefore, PLLA microspheres have a significant effect in promoting tenocyte proliferation, and this effect is significantly enhanced with increasing drug concentration. The inventors tested the effects of polymer microspheres on ligament cells using the same method and obtained the same effect, demonstrating that PLLA microspheres have a significant effect in promoting ligament cell proliferation.

[0041] Example 4 Effects of PLLA microspheres and PLGA microspheres on tendon growth in experimental animals

[0042] Experimental animals: C57BL mice weighing 25±3 g (male and female, 1:1 ratio) were divided into two groups, with 10 mice in each group.

[0043] Experimental site: right Achilles tendon of mice.

[0044] Experimental groups:

[0045] (1) 0.5 mg PLLA microsphere group (Example 1);

[0046] (2) 0.5 mg PLGA microsphere group (Example 2).

[0047] Experimental Procedure: The anatomical location of the right Achilles tendon of the mouse was determined. The dorsal skin of the distal tibia was disinfected with an alcohol cotton ball. A 26G needle and a 1mL sterile syringe were used to inject into the Achilles tendon (the needle should be injected at an angle of 15-30° to the Achilles tendon to avoid puncturing the tendon). The right side was designated as the experimental side (in situ injection of PLLA microspheres or PLGA microspheres in saline solution, only one injection, with a dose of L-lactic acid in the saline solution of 69.44 mmol / L for PLLA microspheres and 52.08 mmol / L for PLGA microspheres in saline solution). The left side was designated as the control side (injection of saline).

[0048] Three mice in each group were killed 7, 14, and 28 days after surgery, and the experimental and control sides of each mouse were fixed and subjected to histopathological examination.

[0049] 2. Detection method:

[0050] 1) The tissue to be observed was removed, fixed, and then stained with resorcinol fuchsin to observe the effects of the injected microspheres on the tissues at various locations.

[0051] 2) Randomly select the experimental and control sides for sectioning, measure the tissue diameter under a 100x optical microscope, and calculate the average value of the experimental and control sides using the following formula:

[0052] Average value = (3 measurements of animal No. 1 + 3 measurements of animal No. 2 + 3 measurements of animal No. 3) / 9

[0053] 3. Experimental results:

[0054] The experimental results are shown in Figures 4 and 5. After injection of 0.5 mg of either PLLA or PLGA microspheres, the experimental-side tendon tissue in both groups showed varying degrees of significant thickening. The figures show that collagen fibers (red) were extensive on the experimental side at days 7, 14, and 28, indicating significant tendon thickening and increased Achilles tendon diameter. Table 1 lists the average Achilles tendon diameters for the experimental and control sides of the two groups.

[0055] The tendon tissue values ​​measured under a 100x optical microscope are shown in Table 1: Compared with the control side, the difference in Achilles tendon diameter between the experimental side treated with 0.5 mg PLLA microspheres on the 14th and 28th days was statistically significant (P<0.05). The Achilles tendon diameter increased in both cases, showing a significant promotion effect on tendon growth; Compared with the control side, the difference in Achilles tendon diameter between the experimental side treated with 0.5 mg PLGA microspheres on the 14th and 28th days was statistically significant (P<0.05). The Achilles tendon diameter increased in both cases, showing a significant promotion effect on tendon growth.

[0056] These experimental results demonstrate that PLLA or PLGA microspheres significantly promote tendon regeneration in animals. The inventors further tested the effects of PLLA or PLGA microspheres on animal ligament tissue using the same method and obtained the same results, demonstrating that PLLA or PLGA microspheres also significantly promote ligament regeneration in animals.

[0057] Table 1 Comparison of measured values ​​between the injection side of PLLA microspheres or PLGA microspheres and the control side

[0058] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not limiting. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the purpose and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. Application of polylactic acid and its copolymers in the preparation of drugs for promoting tendon / ligament growth, characterized in that: The molecular weight of the polylactic acid is 400-300000Da, preferably, the molecular weight is 5000-20000Da.

2. The use according to claim 1, characterized in that: The polylactic acid is poly-L-lactic acid.

3. The use according to claim 1, characterized in that: The polylactic acid copolymer includes one or more of polylactic acid-glycolic acid copolymer, polylactic acid-polyethylene glycol copolymer, polyethylene glycol-polylactic acid-glycolic acid copolymer, polylactic acid-chitosan copolymer, and lactide-caprolactone copolymer. Preferably, the polylactic acid copolymer is a polylactic acid-glycolic acid copolymer.

4. The use according to any one of claims 1 to 3, characterized in that: The polylactic acid and its copolymer are in the form of preparation.

5. The use according to claim 4, characterized in that: The preparations include microspheres, micelles, and gels.

6. The use according to claim 4, characterized in that: The preparation further comprises excipients, which include at least one of a stabilizer, a filler, a binder, a surfactant and a lubricant.

7. The use according to claim 6, characterized in that: The surfactant includes one or more of polyethylene glycol, sodium lauryl sulfate, Tween, and Span; the stabilizer includes one or two of carboxymethyl cellulose and mannitol; the filler includes one or more of lactose, mannitol, cyclodextrin, and sorbitol; the binder includes one or more of hydroxypropyl cellulose, methyl cellulose, and polyvinyl pyrrolidone; and the lubricant includes one or more of magnesium stearate, calcium stearate, and stearic acid.

8. The use according to claim 4, characterized in that: The preparation further comprises a first active ingredient, which has the effect of reducing swelling and relieving pain.

9. The use according to claim 8, characterized in that: The first active ingredient includes celecoxib, loxoprofen sodium, phenylbutazone, ibuprofen, and etoricoxib.

10. The use according to claim 7, characterized in that: The dosage of L-lactic acid in the poly-L-lactic acid and its copolymer during at least one administration of the preparation is 8 to 3000 mmol / L, preferably 250 to 750 mmol / L.

11. The use according to claim 5, characterized in that: The particle size of the microspheres ranges from 17 μm to 60 μm.

12. The use according to claim 7, characterized in that: The preparation is an injection, and the dosage of poly-L-lactic acid or its copolymer in the injection is 8 to 3000 mmol / L, preferably 250 to 750 mmol / L or 50 to 100 mmol / L, measured in terms of L-lactic acid.